Form 4: Celldex Therapeutics CEO Anthony Marucci Acquires 300,000 Stock Options

Celldex Therapeutics CEO Anthony S. Marucci was granted 300,000 incentive stock options on June 13, 2024, according to a Form 4 filing with the SEC.

Summary

• Anthony S. Marucci, the President and CEO of Celldex Therapeutics, Inc., was granted 300,000 incentive stock options on June 13, 2024.
• The options were granted pursuant to the company's 2021 Omnibus Equity Incentive Plan.
• The exercise price of the options is $36.43.
• 25% of the options will vest on June 13, 2025, and the remaining options will vest quarterly over the subsequent 12 quarters.
• The options expire on June 13, 2034.

Sentiment

Score: 6

Explanation: The document is a standard SEC filing related to executive compensation. It's neutral in tone and reflects a routine business practice.

Positives

• The grant of stock options aligns the CEO's interests with those of the shareholders.
• The vesting schedule incentivizes long-term performance.

Future Outlook

This document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and align management's interests with those of shareholders.

Comparison to Industry Standards

• Executive compensation packages, including stock options, vary widely across the biotechnology industry depending on company size, stage of development, and performance.
• Comparing Celldex's executive compensation to peers like Regeneron, Incyte, or smaller biotechs would require a more detailed analysis of their compensation structures and company performance.

Stakeholder Impact

• The stock option grant could be viewed positively by shareholders as it incentivizes the CEO to increase shareholder value.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates